Mineralys Therapeutics, Inc. Common Stock
MLYSMineralys Therapeutics, Inc. (MLYS) is a biopharmaceutical company focused on developing therapies for cardiovascular and metabolic diseases. The company utilizes proprietary technology to develop targeted treatments aimed at addressing unmet medical needs, with a particular emphasis on hyperkalemia. Mineralys aims to advance innovative solutions to improve patient outcomes in these therapeutic areas.
Company News
Mineralys Therapeutics presented clinical data for lorundrostat at ASN Kidney Week 2025, demonstrating promising results in reducing blood pressure and albuminuria in chronic kidney disease patients. The company plans to file a New Drug Application with the FDA in late 2025 or early 2026.
Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.
Mineralys Therapeutics presented subgroup analyses from its Phase 3 Launch-HTN trial, demonstrating lorundrostat's efficacy in reducing blood pressure across diverse high-risk patient populations with uncontrolled hypertension, with consistent safety and meaningful clinical results.
Mineralys Therapeutics has priced a public offering of 9,803,921 shares at $25.50 per share, expecting to raise approximately $250 million to fund clinical development and corporate activities.
Mineralys Therapeutics announced positive results from the Phase 3 Launch-HTN trial of its drug lorundrostat for the treatment of uncontrolled or resistant hypertension. The trial demonstrated clinically meaningful and sustained reductions in systolic blood pressure with a favorable safety profile.
